Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities. To read the newsletter please click here
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received Australian Therapeutic Goods Administration (“TGA”) approval for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) announces that it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) for HepaFat-AI, a medical device (software) that is fully automated and uses artificial intelligence (“AI”) to assess liver fat.
Further to the Company’s announcement on 17 October 2017 (‘Collaborative Partnership commences to develop new AI diagnostic tools’), Resonance Health Ltd is pleased to advise that it has developed a new artificial intelligence (AI) tool for the automated review of chest computed tomography (CT) scans of patients with suspected pulmonary embolism (PE).
Resonance Health Ltd is pleased to announce that it has entered into a licence agreement with the Telethon Kids Institute in Perth, Western Australia, and the Erasmus University Medical Centre, in Rotterdam, The Netherlands, for the use of computed tomography (“CT”) datasets that will be used by the Company in the potential development of a …
Resonance Health Limited is pleased to announce that it has filed a provisional patent covering the application of novel Antisense Oligonucleotides (ASOs) to treat liver related disease.
INVESTORS
SUPPORT
PATIENTS
PHYSICIANS